MetaCap

ProMIS Neurosciences (PMN) vs Rein Therapeutics (RNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ProMIS Neurosciences (PMN) has outperformed Rein Therapeutics (RNTX) over the past year, losing 69.9% versus a loss of 77.2%. Over five years, RNTX leads with a -97.5% price change compared with -98.2% for PMN. Rein Therapeutics is the larger company by market cap ($29.1 million vs $28.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PMN-69.90%RNTX-77.24%
+147%+29%-88%
Nov 21, 20251 yearNov 20, 2026
PMN-98.38%RNTX-97.57%
+24%-40%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PMN versus RNTX key metrics
MetricPMNRNTX
Share price$3.16$0.3369
Market cap$28.43M$29.06M
1-day change-1.56%-8.38%
YTD return-53.73%-70.96%
1-year return-69.90%-77.24%
5-year return-98.24%-97.47%
EPS (TTM)$-6.50$-1.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-39.72M$-49.87M
52-week high$27.40$2.10
52-week low$2.78$0.284
Distance from 52-week high-88.47%-83.96%
Analyst consensusnonenone
Avg. price target upside+1248.42%+1680.94%
Average volume164.88K586.68K
Shares outstanding9.00M86.27M
Employees1010
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ProMIS Neurosciences

PMN stock →

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About Rein Therapeutics

RNTX stock →

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

PMN vs RNTX FAQ

Which is bigger, ProMIS Neurosciences or Rein Therapeutics?

Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $28.43M for ProMIS Neurosciences (PMN).

Which stock has performed better over the past year, PMN or RNTX?

PMN returned -69.90% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.

Are ProMIS Neurosciences and Rein Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons